Lack of protection against bacterial infections in patients with advanced cancer treated by biologic response modifiers.
A survey of patients with advanced cancer treated by biologic response modifiers (BRMs), including (i) recombinant interleukin-2 and lymphokine-activated killer cells, (ii) recombinant interleukin-2 and alpha interferon, and (iii) tumor necrosis factor, was done. A total of 52 patients were reviewed. A total of 73 courses of BRMs were administered. Prior to the initiation of therapy, all patients were infection free and not receiving antibiotics. Twelve patients developed bacteremia during treatment with these BRMs. Five of these 12 patients had catheter-related bacteremia. Six patients had bacteremic infections without an obvious source, and one patient had a urinary tract infection with bacteremia. Staphylococcus epidermidis accounted for six of the isolates. Other organisms were Staphylococcus aureus, group B streptococci, viridans group streptococci, and gram-negative bacilli. This was an unexpectedly high incidence of bacterial infections in patients treated with BRMs. These BRMs have been previously shown to be efficacious against infections (by bacteria and other intracellular organisms) in experimental animals. In this study BRMs did not influence host defense mechanisms or offer protection against bacterial infections.
Maoleekoonpairoj
S
S
Division of Neoplastic Diseases, New York Medical College, Valhalla 10595.
Mittelman
A
A
Savona
S
S
Ahmed
T
T
Puccio
C
C
Gafney
E
E
Skelos
A
A
Arnold
P
P
Coombe
N
N
Baskind
P
P
D001424:Bacterial Infections / Q000150:complications* / Q000517:prevention & control; D002404:Catheterization / Q000009:adverse effects; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007370:Interferon Type I / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000276:immunology / Q000628:therapy*; D018805:Sepsis / Q000150:complications / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D007155:Immunologic Factors; D007370:Interferon Type I; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha